Rite Aid partners with Envision Insurance to offer Medicare Part D Rx drug plan
CAMP HILL, Pa. — Medicare Part D beneficiaries will be able to obtain hundreds of generic drugs without any deductible or co-pay under a new program offered by Rite Aid.
The retail pharmacy chain announced Tuesday that it had partnered with Envision Insurance Co. to offer a value-focused prescription drug plan for Medicare Part D Open Enrollment 2012. Rite Aid EnvisionRx Plus offers beneficiaries a plan with a $0 deductible and $0 co-pays, including during the coverage gap, also known as the donut hole.
Beneficiaries can visit www.envisionrxplus.com/riteaid or consult with a pharmacist to find out if their medications are covered under the plan or to enroll, Rite Aid said.
MicroLite Tech introduces Pop-up MicroLites
KAUAI, Hawaii — MicroLite Tech has introduced new micro-sized lighting devices that provide hands-free illumination.
Pop-up MicroLites are compact and durable LED lights that feature an adhesive backing, allowing it to attach to almost any surface, including plastic, metal, wood, leather and cloth, the company said. The Pop-up MicroLite is the first in an entire line of hands-free micro-lighting products being developed by MicroLite Tech.
"Micro-lighting really is an entirely unexplored product category with lots of room for new innovation," MicroLite Tech founder and CEO John Teel said.
Pop-up MicroLites now are available in glossy black and soon will be available in metallic silver and bright white, for a suggested retail price under $10. A magnetic version of the product also soon will be launched.
Lannett gets OK for generic anti-obesity drug
PHILADELPHIA — Lannett has received approval from the Food and Drug Administration to market its version of an anti-obesity drug.
The FDA approved Lannett’s abbreviated new drug application for diethylpropion hydrochloride extended-release tablets in the 75-mg strength. The company expects to begin shipping the product immediately.
“This approval fills out our portfolio of diethylpropion HCl products and adds to our growing portfolio of anti-obesity medications,” Lannett president and CEO Arthur Bedrosian said. “Since June 24, we have received five product approvals, the most in a four-month period in the company’s history, and a significant achievement for our team. Our pipeline remains deep, with a number of ANDAs currently pending at the FDA, several of which we expect to be approved over the next couple of quarters.”